57 related articles for article (PubMed ID: 15205194)
1. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Kuehr T; Ruff P; Rapoport BL; Falk S; Daniel F; Jacobs C; Davidson N; Thaler J; Boussard B; Carmichael J
BMC Cancer; 2004 Jul; 4():36. PubMed ID: 15257756
[TBL] [Abstract][Full Text] [Related]
3. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Blanke CD; Bot BM; Thomas DM; Bleyer A; Kohne CH; Seymour MT; de Gramont A; Goldberg RM; Sargent DJ
J Clin Oncol; 2011 Jul; 29(20):2781-6. PubMed ID: 21646604
[TBL] [Abstract][Full Text] [Related]
4. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Endo I; Ichikawa Y
Medicine (Baltimore); 2017 May; 96(19):e6769. PubMed ID: 28489753
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.
Kim SY; S Hong Y; K Shim E; Kong SY; Shin A; Baek JY; Jung KH
Br J Cancer; 2013 Sep; 109(6):1420-7. PubMed ID: 23963147
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Di Lauro L; Nunziata C; Arena MG; Foggi P; Sperduti I; Lopez M
Br J Cancer; 2007 Sep; 97(5):593-7. PubMed ID: 17667920
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Krishnamurthi SS; Brell JM; Hoppel CL; Egorin MJ; Weaver KC; Li X; Ingalls ST; Zuhowski EG; Schluchter MD; Dowlati A; Cooney MM; Gibbons J; Overmoyer BA; Ivy SP; Remick SC
Cancer Chemother Pharmacol; 2009 Feb; 63(3):441-50. PubMed ID: 18414865
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Veronese ML; Sun W; Giantonio B; Berlin J; Shults J; Davis L; Haller DG; O'Dwyer PJ
Br J Cancer; 2005 May; 92(10):1846-9. PubMed ID: 15870719
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer.
Peinert S; Grothe W; Stein A; Müller LP; Ruessel J; Voigt W; Schmoll HJ; Arnold D
Ther Adv Med Oncol; 2010 May; 2(3):161-74. PubMed ID: 21789132
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer.
Park SH; Jeon SY; Ko KI; Nam E; Bang SM; Cho EK; Shin DB; Lee JH; Lee WK; Chung M
Cancer Res Treat; 2006; 38(3):121-5. PubMed ID: 19771271
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.
McGregor LM; Spunt SL; Santana VM; Stewart CF; Ward DA; Watkins A; Laningham FH; Ivy P; Furman WL; Fouladi M
Cancer; 2009 Feb; 115(3):655-64. PubMed ID: 19117350
[TBL] [Abstract][Full Text] [Related]
12. Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.
Bruera G; Massacese S; Galvano A; Mas AD; Guadagni S; Calvisi G; Ciacco E; Russo A; Ricevuto E;
Oncotarget; 2018 Apr; 9(29):20339-20350. PubMed ID: 29755655
[TBL] [Abstract][Full Text] [Related]
13. Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
Razumovskaya AV; Silkina MO; Nikulin SV; Tonevitsky AG; Alekseev BY
Bull Exp Biol Med; 2024 Mar; 176(5):703-708. PubMed ID: 38724815
[TBL] [Abstract][Full Text] [Related]
14. A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas.
Russo I; Di Paolo V; Crocoli A; Mastronuzzi A; Serra A; Di Paolo PL; Di Giannatale A; Miele E; Milano GM
Front Oncol; 2020; 10():1228. PubMed ID: 32850366
[No Abstract] [Full Text] [Related]
15. Optimized rat models better mimic patients with irinotecan-induced severe diarrhea.
Zheng Z; Du T; Gao S; Yin T; Li L; Zhu L; Singh R; Sun R; Hu M
Toxicol Mech Methods; 2024 Jun; 34(5):572-583. PubMed ID: 38390772
[TBL] [Abstract][Full Text] [Related]
16. [Delayed diarrhea induced by irinotecan: from the perspective of gut microbiota].
Zhang ZY; Duan LP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):507-511. PubMed ID: 38715491
[TBL] [Abstract][Full Text] [Related]
17. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.
Volkova E; Robinson BA; Willis J; Currie MJ; Dachs GU
Oncol Lett; 2014 Feb; 7(2):311-320. PubMed ID: 24396438
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
19. Treatment of colorectal liver metastases.
Ismaili N
World J Surg Oncol; 2011 Nov; 9():154. PubMed ID: 22115124
[TBL] [Abstract][Full Text] [Related]
20. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.
Xu J; Qin X; Wang J; Zhang S; Zhong Y; Ren L; Wei Y; Zeng S; Wan D; Zheng S; ; ;
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1379-96. PubMed ID: 21796415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
